NCT05256290Phase 1, phase 2Recruiting

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Study sponsor: Black Diamond Therapeutics, Inc. · BDTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-03Estimated
Enrollment · participants220Estimated
Source updated2026-11-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.